Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Foretinib||Phase II||Actionable||In a Phase II trial, Foretinib (GSK1363089) treatment resulted in a clinical benefit rate of 46% (17/37) in triple-receptor negative breast cancer patients, which comprised two patients with a partial response and fifteen patients with stable disease (PMID: 27116183; NCT01147484).||27116183|